MTOR and pancreatic neoplasm: Inhibition of the PI3K/AKT/mTOR signaling axis downstream of RAS using the mTOR inhibiting compounds everolimus and temsirolimus has also given promising results in pancreatic cancer cells [25], and in xenograft mouse model of pancreatic cancer [26], but activity in patients appears minimal [27,28].